Literature DB >> 1641653

The evolution of hydroxyurea therapy in chronic myelogenous leukemia.

B J Kennedy1.   

Abstract

The evolution of hydroxyurea as a chemotherapeutic agent has been unique. Hydroxyurea inhibits synthesis of DNA, has antitumor activity, and is myelosuppressive. It has attained a significant role in the management of chronic myelogenous leukemia. A nonrandomized comparison of busulfan and hydroxyurea concluded that hydroxyurea was the preferable agent in the treatment of chronic myelogenous leukemia and was associated with less life-threatening toxicity. Because of its systemic effects, hydroxyurea is also used in the treatment of polycythemia and psoriasis.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1641653

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  11 in total

1.  An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis.

Authors:  M J Starmans-Kool; M M Fickers; M A Pannebakker
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

Review 2.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

3.  Acute mucocutaneous toxicity following high-dose hydroxyurea.

Authors:  H Brincker; B E Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Effects of hydroxyurea on monoclonal antibody production induced by anti-mIgG and LPS stimulation on murine B cell hybridomas.

Authors:  Alicia Martín-López; Asterio Sánchez-Mirón; Francisco García-Camacho; Antonio Contreras-Gómez; Emilio Molina-Grima
Journal:  Cytotechnology       Date:  2010-05-21       Impact factor: 2.058

Review 5.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

6.  Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.

Authors:  A Meyerhans; J P Vartanian; C Hultgren; U Plikat; A Karlsson; L Wang; S Eriksson; S Wain-Hobson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

7.  Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease.

Authors:  Solo Kuvibidila; Rajasekharan P Warrier; Johnson Haynes; Surendra B Baliga
Journal:  Ochsner J       Date:  2015

8.  Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.

Authors:  Caiguo Zhang; Guoqi Liu; Mingxia Huang
Journal:  Front Biol (Beijing)       Date:  2014-01-02

9.  Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox.

Authors:  Mohammed S Inayat; Ismail S El-Amouri; Mohammad Bani-Ahmad; Howard L Elford; Vincent S Gallicchio; Oliver R Oakley
Journal:  J Inflamm (Lond)       Date:  2010-08-18       Impact factor: 4.981

10.  Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.

Authors:  Manar Mohamd Mohamad Ismail; Moneer M Manar
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.